North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane.

Abstract

INTRODUCTION Angiogenesis is an established target for the treatment of MBC. Aflibercept (VEGF-Trap) is a humanized fusion protein, which binds VEGF-A, VEGF-B, and PIGF-1 and -2. PATIENTS AND METHODS A 2-stage phase II study with primary end points of confirmed tumor response and 6-month progression-free survival (PFS). If either end point was promising… (More)
DOI: 10.1016/j.clbc.2012.09.007

Topics

Cite this paper

@article{Sideras2012NorthCC, title={North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane.}, author={Kostandinos Sideras and Amylou Dueck and Timothy J. Hobday and Kendrith M. Rowland and Jacob B Jake Allred and Donald W. Northfelt and Wilma L. Lingle and Robert J. Behrens and Tom R. Fitch and Daniel A. Nikcevich and E. A. S{\'a}nchez P{\'e}rez}, journal={Clinical breast cancer}, year={2012}, volume={12 6}, pages={387-91} }